Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03043313 · ClinicalTrials.gov registry record · Phase 2
Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer
A Phase 2 study, sponsored by Seagen.
- Completed
- Registry status
- Phase 2
- Development phase
- 117
- Enrollment target
NCT03043313 is a Phase 2 study that has completed, run by Seagen. The registered enrollment target is 117 participants.
The verdict
NCT03043313, a Phase 2 study, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 117 participants
- Enrollment target
Study Summary
This trial studies how well the drug tucatinib works when given with trastuzumab and when given by itself. The participants in this trial have HER2-positive (HER2+) metastatic colorectal cancer (mCRC). 'Metastatic' means that the cancer has spread to other parts of the body. In the first part of this study, participants enrolled into Cohort A and received both tucatinib and trastuzumab. In the second part of this study, participants are randomly assigned to either Cohort B or Cohort C. Participants in Cohort B will receive tucatinib and trastuzumab. Participants in Cohort C will receive tucatinib. Participants in Cohort C who do not respond to therapy may have an option to receive tucatinib plus trastuzumab.
Interventions
- DRUG Trastuzumab
- DRUG Tucatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2017-06-23 |
| Est. Completion | 2023-11-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03043313
The ClinicalTrials.gov registry entry for NCT03043313 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Trastuzumab is the first listed.
NCT03043313 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03043313 about?
NCT03043313 is a clinical study titled "Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer". This trial studies how well the drug tucatinib works when given with trastuzumab and when given by itself. The participants in this trial have HER2-positive (HER2+) metastatic colorectal cancer (mCRC). 'Metastatic' means that the cancer has spread to other parts of the body. In the first part of th...
What is the current status of trial NCT03043313?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 117 participants. The study started on 2017-06-23. Estimated completion is 2023-11-02.
What interventions are being tested in trial NCT03043313?
The interventions under investigation include: Trastuzumab (DRUG), Tucatinib (DRUG).
Who is sponsoring clinical trial NCT03043313?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.